MedTrace Logo

Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis

NCT00710788 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2013-02-12

No results posted yet for this study

Summary

Research proposal to evaluate the impact of different phosphate binders on the progression of cardiovascular calcification and QT dispersion in new haemodialysis patients.

Conditions

  • Cardiovascular Mortality

Interventions

DRUG

sevelamer phosphate-binders

1600 mg/day for 2 years

DRUG

Calcium Carbonate

Calcium carbonate 1 g/day for 2 years

Sponsors & Collaborators

  • Azienda Sanitaria ASL Avellino 2

    lead OTHER

Principal Investigators

  • Biagio R Di Iorio, MD, PhD · ASL AV/2, Avellino, Italy

  • Loreto Gesualdo, professor · Nephrology Division, Medical School, University of Foggia

  • Filippo Aucella, MD · ASL FG, Italy

  • Walter De Simone, MD · AO MOscati, Avellino, Italy

  • Mario Migliorati, MD · Dialysis, Torre del Greco, Italy

  • Domenico Santoro, MD · Nephrology Division, Medical School, University of Messina, Italy

  • Pasquale Guastaferro, MD · Nephrology Division, ASL AV1, Sant'Angelo de Lomnardi, Italy

  • Luigi Chiuchuilo, MD · Dialysis, Avellino, Italy

  • Vincenzo Tedesco, MD · Dialysis, Montella, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-09-30
Completion
2011-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710788 on ClinicalTrials.gov